

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Caput, Daniel Ferrara, Pascual Laurent, Patrick Vita, Natalio

- (ii) TITLE OF INVENTION: IL-13 receptor
- (iii) NUMBER OF SEQUENCES: 4
 - (iv) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
- (2) INFORMATION FOR SEQ ID NO: 1:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1539 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: CONA
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
 - (F) TISSUE TYPE: Carcinoma
 - (G) CELL TYPE: renal
 - (H) CELL LINE: caki-1
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GGTGCCTGTC GGCGGGGAGA GAGGCAATA CAAGGTTTTA AATCTCGGAG AAATGGCTTA 60 ATTCGTTTGC TTGGCTATCG GATGCTTATA TACCTTTCTG ATAAGCACAA CATTTGGCTG 120 TACAAGCTTT TGCACTTCAT CTTCAGACAC CGA ATAAAA GTTAACCCT CTCAGGATTT 180 TGAGATAGTG GATTATGAAG AGAACCCGGA TACTTAGGTT ATCTCTATTT GCAATGGCAA 240 CCCCCACTGT CTCTGGATCA/TTTTGTGTTG TGAAAGGAAT GCACAGTGGA ATATGAACTA 300 AAATACCGAA ACATTGGTAG TGAAACATGG AAGGCTAGTG TAGAGGTTAC CATCATTACT 360 AAGAATCTAC ATTACAAGA TGGGTTTGAT CTTAACAAGG GCATTGAATT ATAGAAGGGC 420 GAAGATACAC ACGATTTTAC CATGGCAATG CACAAATGGA TCAGAAGTTC AAAGTTCCAA 480 TTGCTAGGAG TAGGCAGAAA CTACTTATTG GATATCACCA CAAGGAATTC CAGAAACTAA 540 AGTTCAGGAT/TAAGTTTTGG GTAGAATGGA TTGCGTATAT TACAATTGGC AATATTTACT 600 CTGTTCTT#G AAACCTGGCA TAGGTTACAT TATGTCTGGG TACTTCTTGA TACCAATTAC 660 AACTTGTTTT ACTGGTATGA GGGCTTGGAT CATGCATTAA ATATATTTGG AAACAGTGTG 720

TTGATTACAT CAAGGCTGAT GGACAAAATA TAGGATGCAG ATTTCCCTAT TTGGCAATAA 780 AGGAGCAGTG AGGCATCAGA CTATAAAGAT TTCTATATTT GTGTTAATGG ATCATCAGAG 840 AACAAGCCTG AAATATCAAG GAATCAGATC CAGTTATTTC ACTTTTCAGC TTCAAAATAT 900 AGTTAAACCT TTGCCGCCAG TCAGTTGGAA ATATCTTACT TTTACTCGGG AGAGTTCATG 960 TGAAATTAAG CTGAAATGGA GCATACCTTT GTTTAGGCGT GGACCTATTC CAGCAAGGTG 1020 TTTTGATTAT GAAATTGAGA TCAGAGAAGA TGATACTACC GAAAGCATGG AGGAATTTTG 1080 GTGACTGCTA CAGTTGAAAA TGAAACATAC ACCTTGAAAA CAACAAATGA AACCCGAATA 1140 ATAGAGTTTT TAGTAGCAAT TATGCTTTGT AGTAAGAAGC AAAGTGAATA TTTATTGCTC 1200 AGATGACGGA ATTTGGGCAA AGAATCAAGT AGTGAGTGGA GTGATAAACA ATGCTGGGAA 1260 GGTGAAGACC TATCGAAGAA AACTTTGCTA GTAGCTGGGA TCGTTTCTGG CTACCATTTG 1320 GTTTCATCTT AATATTAGTT ATATTTGTAA CCGGTCTGCT TAGTGAATGT TGCGTAAGCC 1380 AAACACCTAC CCAAAAATGA TTCCAGAATT TTTCTGTGAT ACATGAAGAA GATTTGCATC 1440 TTTCCATATC AAGAGACATG GTATTGACTC AACAGTTTCC AGTCATGGCC AAATGTTCAA 1500 TATGAGTCTC AATAAACTGA ATTTTTCTTG CGAATGTTG 1539



(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 380 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
 - (F) TISSUE TYPE: Carcinoma
 - (G) CELL TYPE: renal
 - (H) CELL LINE: Caki-1

(xi) SEQUENCE DESCRIPTION: SEO ID NO: 2:

Ser Thr Thr Phe Gly Cys Thr Ser Ser Ser Asp Thr Glu Ile Lys Val 20 25 30

Asn Pro Pro Gln Asp Phe Glu Ile Val Asp Pro Gly Tyr Leu Gly Tyr 35 40 45

Leu Tyr Leu Gln Trp Gln Pro Pro Leu Ser Leu Asp His Phe Lys Glu 50 55 60

Cys Thr Val Glu Tyr Glu Leu Lys Tyr Arg Asn Ile Gly Ser Glu Thr 65 70 75 80

Trp Lys Thr Ile Ile Thr Lys Asn Leu His Tyr Lys Asp Gly Phe Asp

90 95

Leu Asn Lys Gly Ile Glu Ala Lys Ile His Thr Leu Leu Pro Trp Gln 100 Cys Thr Asn Gly Ser Glu Val Gln Ser Ser Trp Ala Glu Thr Thr Tyr 120 Trp Ile Ser Pro Gln Gly Ile Pro Glu Thr Lys Val Gln Asp Met Asp 135 Cys Val Tyr Tyr Asn Trp Gln Tyr Leu Leu Cys Ser Trp Lys Pro Gly 150 Ile Gly Val Leu Leu Asp Thr Asn Tyr Asn Leu Phe Tyr Trp Tyr Glu Gly Leu Asp His Ala Leu Gln Cys Val Asp Tyr Ile Lys Ala Asp Gly 185 Gln Asn Ile Gly Cys Arg Phe Pro Tyr Leu Glu Ala Ser Asp Tyr Lys Asp Phe Tyr Ile Cys Val Asn Gly Ser Ser Glu Asn Lys Pro Ile Arg 215 220 Ser Ser Tyr Phe Thr Phe Gln Leu Gln Asn Ile Val Lys Pro Leu Pro 230 235 Pro Val Tyr Leu Thr Phe Thr Arg Glu Ser Ser Cys Glu Ile Lys Leu Lys Trp Ser Ile Pro Leu Gly Pro Ile Pro Ala Arg Cys Phe Asp Tyr Glu Ile Glu Île Arg Glu Asp Asp Thr Thr Leu Val Thr Ala Thr Val 280 285 Glu Asn Glu Thr Tyr Thr Leu Lys Thr Thr Asn Glu Thr Arg Gln Leu 295 Cys Phe Val Val Arg Ser Lys Val Asn Ile Tyr Cys Ser Asp Asp Gly Ile Trp Ser Glu Trp Ser Asp Lys Gln Cys Trp Glu Gly Glu Asp Leu Ser Lys Lys Thr Leu Leu Arg Phe Trp Leu Pro Phe Gly Phe Ile Leu 345 Ile Leu Val Ile Phe Val Thr Gly Leu Leu Leu Arg Lys Pro Asn Thr 360 Tyr Pro Lys Met Ile Pro Glu Phe Phe Cys Asp Thr 375

- (2) INFORMATION FOR SEQ ID NO: 3:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4009 base pairs
 - (B) TYPE: nucleic acid



(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens(F) TISSUE TYPE: Carcinoma
- (G) CELL TYPE: RENAL
 (H) CELL LINE: Caki-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TCAGCCCGGC CGGGCTCCGA GGCGAGAGGC TGCATGGAGT GGCCGGCGC GCTCTGCGGG 60 CTGTGGGCGC TGCTGCTCTG CGCCGGCGGC GGGGGCGGG GCGGGGGGCGC CGCGCCTACG 120 GAAACTCAGC CACCTGTGAC AAATTTGAGT GTCTCTGTTG AAAACCTCTG CACAGTAATA 180 TGGACATGGA ATCCACCCGA GGGAGCCAGC TCAAATTGTA GTCTATGGTA TTTTAGTCAT 240 TTTGGCGACA AACAAGATAA GAAAATAGCT CCGGAAACTC GTCGTTCAAT AGAAGTACCC 300 CTGAATGAGA GGATTTGTCT GCAAGTGGGG TCCCAGTGTA GCACCAATGA GAGTGAGAAG 360 CCTAGCATTT TGGTTGAAAA ATGCATCTCA CCCCCAGAAG GTGATCCTGA GTCTGCTGTG 420 ACTGAGCTTC AATGCATTTG GCACAACCTG AGCTACATGA AGTGTTCTTG GCTCCCTGGA 480 AGGAATACCA GTCCCGACAC TAACTATACT CTCTACTATT GGCACAGAAG CCTGGAAAAA 540 ATTCATCAAT GTGAAAACAT CTTTAGAGAA GGCCAATACT TTGGTTGTTC CTTTGATCTG 600 ACCAAAGTGA AGGATTCCAG TTTTGAACAA CACAGTGTCC AAATAATGGT CAAGGATAAT 660 GCAGGAAAAA TTAAACCATC CTTCAATATA GTGCCTTTAA CTTCCCGTGT GAAACCTGAT 720 CCTCCACATA TTAAAAACCT CTCCTTCCAC AATGATGACC TATATGTGCA ATGGGAGAAT 780 CCACAGAATT TTATTAGCAG ATGCCTATTT TATGAAGTAG AAGTCAATAA CAGCCAAACT 840 GAGACACATA ATGTTTTCTA CGTCCAAGAG GCTAAATGTG AGAATCCAGA ATTTGAGAGA 900 AATGTGGAGA ATACATCTTG TTTCATGGTC CCTGGTGTTC TTCCTGATAC TTTGAACACA 960 GTCAGAATAA GAGTCAAAAC AAATAAGTTA TGCTATGAGG ATGACAAACT CTGGAGTAAT 1020 TGGAGCCAAG AAATGAGTAT AGGTAAGAAG CGCAATTCCA CACTCTACAT AACCATGTTA 1080 CTCATTGTTC CAGTCATCGT CGCAGGTGCA ATCATAGTAC TCCTGCTTTA CCTAAAAAGG 1140 CTCAAGATTA TTATATTCCC TCCAATTCCT GATCCTGGCA AGATTTTTAA AGAAATGTTT 1200 GGAGACCAGA ATGATGATAC TCTGCACTGG AAGAAGTACG ACATCTATGA GAAGCAAACC 1260 AAGGAGGAAA CCGACTCTGT AGTGCTGATA GAAAACCTGA AGAAAGCCTC TCAGTGATGG 1320



AGATAATTTA TTTTTACCTT CACTGTGACC TTGAGAAGAT TCTTCCCATT CTCCATTTGT 1380 TATCTGGGAA CTTATTAAAT GGAAACTGAA ACTACTGCAC CATTTAAAAA CAGGCAGCTC 1440 ATAAGAGCCA CAGGTCTTTA TGTTGAGTCG CGCACCGAAA AACTAAAAAT AATGGGCGCT 1500 TTGGAGAGA GTGTGGAGTC ATTCTCATTG AATTATAAAA GCCAGCAGGC TTCAAACTAG 1560 GGGACAAAGC AAAAAGTGAT GATAGTGGTG GAGTTAATCT TATCAAGAGT TGTGACAACT 1620 TCCTGAGGGA TCTATACTTG CTTTGTGTTC TTTGTGTCAA CATGAACAAA TTTTATTTGT 1680 AGGGGAACTC ATTTGGGGTG CAAATGCTAA TGTCAAACTT GAGTCACAAA GAACATGTAG 1740 AAAACAAAAT GGATAAAATC TGATATGTAT TGTTTGGGAT CCTATTGAAC CATGTTTGTG 1800 GCTATTAAAA CTCTTTTAAC AGTCTGGGCT GGGTCCGGTG GCTCACGCCT GTAATCCCAG 1860 CAATTTGGGA GTCCGAGGCG GGCGGATCAC TCGAGGTCAG GAGTTCCAGA CCAGCCTGAC 1920 CAAAATGGTG AAACCTCCTC TCTACTAAAA CTACAAAAAT TAACTGGGTG TGGTGGCGCG 1980 TGCCTGTAAT CCCAGCTACT CGGGAAGCTG AGGCAGGTGA ATTGTTTGAA CCTGGGAGGT 2040 GGAGGTTGCA GTGAGCAGAG ATCACACCAC TGCACTCTAG CCTGGGTGAC AGAGCAAGAC 2100 TCTGTCTAAA AAACAAAACA AAACAAAACA AAACAAAAAA ACCTCTTAAT ATTCTGGAGT 2160 CATCATTCCC TTCGACAGCA TTTTCCTCTG CTTTGAAAGC CCCAGAAATC AGTGTTGGCC 2220 ATGATGACAA CTACAGAAAA ACCAGAGGCA GCTTCTTTGC CAAGACCTTT CAAAGCCATT 2280 TTAGGCTGTT AGGGGCAGTG GAGGTAGAAT GACTCCTTGG GTATTAGAGT TTCAACCATG 2340 AAGTCTCTAA CAATGTATTT TCTTCACCTC TGCTACTCAA GTAGCATTTA CTGTGTCTTT 2400 GGTTTGTGCT AGGCCCCGG GTGTGAAGCA CAGACCCCTT CCAGGGGTTT ACAGTCTATT 2460 TGAGACTCCT CAGTTCTTGC CACTTTTTT TTTAATCTCC ACCAGTCATT TTTCAGACCT 2520 TTTAACTCCT CAATTCCAAC ACTGATTTCC CCTTTTGCAT TCTCCCTCCT TCCCTTCCTT 2580 GTAGCCTTTT GACTTTCATT GGAAATTAGG ATGTAAATCT GCTCAGGAGA CCTGGAGGAG 2640 CAGAGGATAA TTAGCATCTC AGGTTAAGTG TGAGTAATCT GAGAAACAAT GACTAATTCT 2700 TGCATATTTT GTAACTTCCA TGTGAGGGTT TTCAGCATTG ATATTTGTGC ATTTTCTAAA 2760 CAGAGATGAG GTGGTATCTT CACGTAGAAC ATTGGTATTC GCTTGAGAAA AAAAGAATAG 2820 TTGAACCTAT TTCTCTTTCT TTACAAGATG GGTCCAGGAT TCCTCTTTTC TCTGCCATAA 2880 ATGATTAATT AAATAGCTTT TGTGTCTTAC ATTGGTAGCC AGCCAGCCAA GGCTCTGTTT 2940 ATGCTTTTGG GGGGCATATA TTGGGTTCCA TTCTCACCTA TCCACACAAC ATATCCGTAT 3000 ATATCCCCTC TACTCTTACT TCCCCCAAAT TTAAAGAAGT ATGGGAAATG AGAGGCATTT 3060 CCCCCACCC ATTTCTCTC TCACACAG ACTCATATTA CTGGTAGGAA CTTGAGAACT 3120 TTATTTCCAA GTTGTTCAAA CATTTACCAA TCATATTAAT ACAATGATGC TATTTGCAAT 3180

4

200

TCCTGCTCCT AGGGGAGGG AGATAAGAAA CCCTCACTCT CTACAGGTTT GGGTACAAGT 3240 GGCAACCTGC TTCCATGGCC GTGTAGAAGC ATGGTGCCCT GGCTTCTCTG AGGAAGCTGG 3300 GGTTCATGAC AATGGCAGAT GTAAAGTTAT TCTTGAAGTC AGATTGAGGC TGGGAGACAG 3360 CCGTAGTAGA TGTTCTACTT TGTTCTGCTG TTCTCTAGAA AGAATATTTG GTTTTCCTGT 3420 ATAGGAATGA GATTAATTCC TTTCCAGGTA TTTTATAATT CTGGGAAGCA AAACCCATGC 3480 CTCCCCTAG CCATTTTAC TGTTATCCTA TTTAGATGGC CATGAAGAGG ATGCTGTGAA 3540 ATTCCCAACA AACATTGATG CTGACAGTCA TGCAGTCTGG GAGTGGGGAA GTGATCTTTT 3600 GTTCCCATCC TCTTCTTTA GCAGTAAAAT AGCTGAGGGA AAAGGGAGGG AAAAGGAAGT 3660 TATGGGAATA CCTGTGGTGG TTGTGATCCC TAGGTCTTGG GAGCTCTTGG AGGTGTCTGT 3720 ATCAGTGGAT TTCCCATCCC CTGTGGGAAA TTAGTAGGCT CATTTACTGT TTTAGGTCTA 3780 GCCTATGTGG ATTTTTCCT AACATACCTA AGCAAACCCA GTGTCAGGAT GGTAATTCTT 3840 ATTCTTTCGT TCAGTTAAGT TTTTCCCTTC ATCTGGGCAC TGAAGGGATA TGTGAAACAA 3900 TGTTAACATT TTTGGTAGTC TTCAACCAGG GATTGTTTCT GTTTAACTTC TTATAGGAAA 3960 GCTTGAGTAA AATAATATT GTCTTTTTGT ATGTCACCCA AAAAAAAA 4009

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 427 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
 - (F) TISSUE TYPE: Carcinoma
 - (G) CELL TYPE: renal
 - (H) CELL LINE: Caki-1
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Glu Trp Pro Ala Arg Leu Cys Gly Leu Trp Ala Leu Leu Cys
1 10 15

Ala Gly Gly Gly Gly Gly Gly Gly Ala Ala Pro Thr Glu Thr Gln . 20 25 30

Pro Pro Val Thr Asn Leu Ser Val Ser Val Glu Asn Leu Cys Thr Val 35 40 45

Ile Trp Thr Trp Asn Pro Pro Glu Gly Ala Ser Ser Asn Cys Ser Leu 50 55 60

Trp Tyr Phe Ser His Phe Gly Asp Lys Gln Asp Lys Lys Ile Ala Pro 65 70 75 80

Glu Thr Arg Arg Ser Ile Glu Val Pro Leu Asn Glu Arg Ile Cys Leu 85 90 95

(ú)

Gln Val Gly Ser Gln Cys Ser Thr Asn Glu Ser Glu Lys Pro Ser Ile 100 105 Leu Val Glu Lys Cys Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala 120 Val Thr Glu Leu Gln Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser Trp Leu Pro Gly Arg Asn Thr Ser Pro Asp Thr Asn Tyr Thr Leu 155 Tyr Tyr Trp His Arg Ser Leu Glu Lys Ile His Gln Cys Glu Asn Ile Phe Arg Glu Gly Gln Tyr Phe Gly Cys Ser Phe Asp Leu Thr Lys Val Lys Asp Ser Ser Phe Glu Gln His Ser Val Gln Ile Met Val Lys Asp 200 Asn Ala Gly Lys Ile Lys Pro Ser Phe Asn Ile Val Pro Leu Thr Ser Arg Val Lys Pro Asp Pro Pro His Ile Lys Asn Leu Ser Phe His Asn 235 Asp Asp Leu Tyr Val Gln Trp Glu Asn Pro Gln Asn Phe Ile Ser Arg 250 Cys Leu Phe Tyr Glu Val Glu Val Asn Asn Ser Gln Thr Glu Thr His 265 Asn Val Phe Tyr Val Gln Glu Ala Lys Cys Glu Asn Pro Glu Phe Glu Arg Asn Val Glu Asn Thr Ser Cys Phe Met Val Pro Gly Val Leu Pro Asp Thr Leu Asn Thr Val Arg Ile Arg Val Lys Thr Asn Lys Leu Cys 310 Tyr Glu Asp Asp Lys Leu Trp Ser Asn Trp Ser Gln Glu Met Ser Ile 330 Gly Lys Lys Arg Asn Ser Thr Leu Tyr Ile Thr Met Leu Leu Ile Val 345 Pro Val Ile Val Ala Gly Ala Ile Ile Val Leu Leu Tyr Leu Lys 360 Arg Leu Lys Ile Ile Ile Phe Pro Pro Ile Pro Asp Pro Gly Lys Ile Phe Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu His Trp Lys Lys Tyr Asp Ile Tyr Glu Lys Gln Thr Lys Glu Glu Thr Asp Ser Val 410 Val Leu Ile Glu Asn Leu Lys Lys Ala Ser Gln

 A_{1}